Dosing Nucleoside Reverse Transcriptase Inhibitors in Adults Receiving Continuous Veno-Venous Hemofiltration

Milena M. McLaughlin, Abeer T. Ammar, Lana Gerzenshtein, Kimberly K Scarsi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Conclusion: Clinicians should utilize these recommendations in the context of each individual patient, taking into consideration patient-specific factors and severity of illness. Future pharmacokinetic research correlating plasma and intracellular concentrations of NRTIs during CVVH is warranted to elucidate appropriate dosing.

Background and Objective: Characteristics of nucleoside reverse transcriptase inhibitors (NRTIs) make the drug class susceptible to elimination via continuous veno-venous hemofiltration (CVVH), potentially leading to suboptimal drug concentrations if given at the recommended anephric doses during CVVH. The objective of this study was to formulate NRTI dosing recommendations for adults receiving CVVH.

Methods: A mathematical formula that estimates the amount of drug likely to be removed during CVVH at various flow rates was used to calculate the supplemental NRTI dose required during CVVH.

Results: A proposed table of dosing recommendations for NRTIs during CVVH is presented.

Original languageEnglish (US)
Pages (from-to)275-280
Number of pages6
JournalClinical Drug Investigation
Volume35
Issue number4
DOIs
StatePublished - Mar 21 2015

Fingerprint

Hemofiltration
Reverse Transcriptase Inhibitors
Nucleosides
Pharmaceutical Preparations
Pharmacokinetics
Research

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Dosing Nucleoside Reverse Transcriptase Inhibitors in Adults Receiving Continuous Veno-Venous Hemofiltration. / McLaughlin, Milena M.; Ammar, Abeer T.; Gerzenshtein, Lana; Scarsi, Kimberly K.

In: Clinical Drug Investigation, Vol. 35, No. 4, 21.03.2015, p. 275-280.

Research output: Contribution to journalArticle

McLaughlin, Milena M. ; Ammar, Abeer T. ; Gerzenshtein, Lana ; Scarsi, Kimberly K. / Dosing Nucleoside Reverse Transcriptase Inhibitors in Adults Receiving Continuous Veno-Venous Hemofiltration. In: Clinical Drug Investigation. 2015 ; Vol. 35, No. 4. pp. 275-280.
@article{aae6acd732994f8d8c2d5aa9482dd68d,
title = "Dosing Nucleoside Reverse Transcriptase Inhibitors in Adults Receiving Continuous Veno-Venous Hemofiltration",
abstract = "Conclusion: Clinicians should utilize these recommendations in the context of each individual patient, taking into consideration patient-specific factors and severity of illness. Future pharmacokinetic research correlating plasma and intracellular concentrations of NRTIs during CVVH is warranted to elucidate appropriate dosing.Background and Objective: Characteristics of nucleoside reverse transcriptase inhibitors (NRTIs) make the drug class susceptible to elimination via continuous veno-venous hemofiltration (CVVH), potentially leading to suboptimal drug concentrations if given at the recommended anephric doses during CVVH. The objective of this study was to formulate NRTI dosing recommendations for adults receiving CVVH.Methods: A mathematical formula that estimates the amount of drug likely to be removed during CVVH at various flow rates was used to calculate the supplemental NRTI dose required during CVVH.Results: A proposed table of dosing recommendations for NRTIs during CVVH is presented.",
author = "McLaughlin, {Milena M.} and Ammar, {Abeer T.} and Lana Gerzenshtein and Scarsi, {Kimberly K}",
year = "2015",
month = "3",
day = "21",
doi = "10.1007/s40261-015-0275-9",
language = "English (US)",
volume = "35",
pages = "275--280",
journal = "Clinical Drug Investigation",
issn = "1173-2563",
publisher = "Adis International Ltd",
number = "4",

}

TY - JOUR

T1 - Dosing Nucleoside Reverse Transcriptase Inhibitors in Adults Receiving Continuous Veno-Venous Hemofiltration

AU - McLaughlin, Milena M.

AU - Ammar, Abeer T.

AU - Gerzenshtein, Lana

AU - Scarsi, Kimberly K

PY - 2015/3/21

Y1 - 2015/3/21

N2 - Conclusion: Clinicians should utilize these recommendations in the context of each individual patient, taking into consideration patient-specific factors and severity of illness. Future pharmacokinetic research correlating plasma and intracellular concentrations of NRTIs during CVVH is warranted to elucidate appropriate dosing.Background and Objective: Characteristics of nucleoside reverse transcriptase inhibitors (NRTIs) make the drug class susceptible to elimination via continuous veno-venous hemofiltration (CVVH), potentially leading to suboptimal drug concentrations if given at the recommended anephric doses during CVVH. The objective of this study was to formulate NRTI dosing recommendations for adults receiving CVVH.Methods: A mathematical formula that estimates the amount of drug likely to be removed during CVVH at various flow rates was used to calculate the supplemental NRTI dose required during CVVH.Results: A proposed table of dosing recommendations for NRTIs during CVVH is presented.

AB - Conclusion: Clinicians should utilize these recommendations in the context of each individual patient, taking into consideration patient-specific factors and severity of illness. Future pharmacokinetic research correlating plasma and intracellular concentrations of NRTIs during CVVH is warranted to elucidate appropriate dosing.Background and Objective: Characteristics of nucleoside reverse transcriptase inhibitors (NRTIs) make the drug class susceptible to elimination via continuous veno-venous hemofiltration (CVVH), potentially leading to suboptimal drug concentrations if given at the recommended anephric doses during CVVH. The objective of this study was to formulate NRTI dosing recommendations for adults receiving CVVH.Methods: A mathematical formula that estimates the amount of drug likely to be removed during CVVH at various flow rates was used to calculate the supplemental NRTI dose required during CVVH.Results: A proposed table of dosing recommendations for NRTIs during CVVH is presented.

UR - http://www.scopus.com/inward/record.url?scp=84925495835&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925495835&partnerID=8YFLogxK

U2 - 10.1007/s40261-015-0275-9

DO - 10.1007/s40261-015-0275-9

M3 - Article

C2 - 25691260

AN - SCOPUS:84925495835

VL - 35

SP - 275

EP - 280

JO - Clinical Drug Investigation

JF - Clinical Drug Investigation

SN - 1173-2563

IS - 4

ER -